Kerala High Court seeks reports on whether cheaper alternative can substitute patented cancer drug
The Kerala High Court has requested expert reports to determine if cheaper breast cancer drugs can be substituted for expensive patented ones. This follows a petition regarding the high cost of life-saving medication and the potential for government intervention under patent laws.
The Kerala High Court has directed the National Cancer Institute, Jhajjar; Chittaranjan National Cancer Institute, Kolkata; the Regional Cancer Centre (RCC), Thiruvananthapuram; and the Drug Controller General of India (DCGI) to file reports on whether Ribociclib and Palbociclib, medicines used in breast cancer treatment, can be substituted for each other.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in